Nanoviricides Inc (NNVC)
1.07
-0.08
(-6.96%)
USD |
NYAM |
Apr 25, 12:29
Nanoviricides Enterprise Value: 8.300M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 8.300M |
| April 23, 2024 | 8.183M |
| April 22, 2024 | 7.947M |
| April 19, 2024 | 7.712M |
| April 18, 2024 | 8.595M |
| April 17, 2024 | 8.418M |
| April 16, 2024 | 8.654M |
| April 15, 2024 | 8.300M |
| April 12, 2024 | 9.478M |
| April 11, 2024 | 9.714M |
| April 10, 2024 | 10.19M |
| April 09, 2024 | 10.77M |
| April 08, 2024 | 11.13M |
| April 05, 2024 | 10.89M |
| April 04, 2024 | 10.89M |
| April 03, 2024 | 9.832M |
| April 02, 2024 | 9.714M |
| April 01, 2024 | 10.07M |
| March 28, 2024 | 8.418M |
| March 27, 2024 | 8.065M |
| March 26, 2024 | 8.183M |
| March 25, 2024 | 8.065M |
| March 22, 2024 | 8.183M |
| March 21, 2024 | 8.183M |
| March 20, 2024 | 8.300M |
| Date | Value |
|---|---|
| March 19, 2024 | 8.300M |
| March 18, 2024 | 8.300M |
| March 15, 2024 | 8.889M |
| March 14, 2024 | 8.536M |
| March 13, 2024 | 8.065M |
| March 12, 2024 | 8.065M |
| March 11, 2024 | 7.947M |
| March 08, 2024 | 7.829M |
| March 07, 2024 | 8.065M |
| March 06, 2024 | 8.418M |
| March 05, 2024 | 9.007M |
| March 04, 2024 | 9.007M |
| March 01, 2024 | 9.596M |
| February 29, 2024 | 10.66M |
| February 28, 2024 | 10.30M |
| February 27, 2024 | 10.42M |
| February 26, 2024 | 10.42M |
| February 23, 2024 | 10.42M |
| February 22, 2024 | 9.714M |
| February 21, 2024 | 9.361M |
| February 20, 2024 | 9.361M |
| February 16, 2024 | 9.243M |
| February 15, 2024 | 8.772M |
| February 14, 2024 | 8.536M |
| February 13, 2024 | 7.947M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.466M
Minimum
May 12 2022
124.76M
Maximum
Jan 31 2020
19.01M
Average
12.57M
Median
Jan 15 2020
Enterprise Value Benchmarks
| Gilead Sciences Inc | 101.21B |
| NovaBay Pharmaceuticals Inc | 2.284M |
| Palatin Technologies Inc | 18.43M |
| iBio Inc | 16.49M |
| Theriva Biologics Inc | -13.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.115M |
| Total Expenses (Quarterly) | 2.185M |
| EPS Diluted (Quarterly) | -0.18 |
| Earnings Yield | -75.70% |